WISD yields 2.17% · JNJ yields 2.13%● Live data
📍 JNJ pulled ahead of the other in Year 7
Combined, WISD + JNJ cover 0 of 12 months — good coverage
Which stock is actually better after tax? Adjust your rate to find out.
What's the optimal mix of WISD + JNJ for your $10,000?
WISD broadly invests in global fixed-income securities with a short duration of one year or less. The funds portfolio includes US and foreign bonds, debt securities, commercial paper, mortgage-backed securities, floating-rate securities, and up to 30% in asset-backed securities, such as CLOs rated investment-grade. Junk bonds are limited to 15% of net assets. The fund may invest up to 50% in foreign-denominated securities, including 10% in emerging markets. Foreign currency exposure is capped at 10% using derivatives such as treasury and bond futures, swaps, and credit default swaps to hedge interest rate and currency risks. The fund may have a higher portfolio turnover rate due to active and frequent trading. Prior to November 11, 2025, the fund operated as a mutual fund before converting to an actively managed ETF structure, launching with $368.81 million in assets.
Full WISD Calculator →Johnson & Johnson, together with its subsidiaries, researches and develops, manufactures, and sells various products in the healthcare field worldwide, but strategically separated its Consumer Health business into Kenvue Inc. in 2023 to focus on its higher-growth, innovation-driven segments; the former Consumer Health brands (including TYLENOL, LISTERINE, and BAND-AID) are now owned by Kenvue. The company's core focus is now split between its Innovative Medicine (formerly Pharmaceutical) segment, which offers prescription products for complex diseases such as rheumatoid arthritis, various cancers, HIV/AIDS, and neurodegenerative disorders; and its MedTech (Medical Devices) segment, which provides advanced technology solutions including electrophysiology products, neurovascular care products, orthopaedics (hips, knees, spine), advanced surgery solutions, and disposable contact lenses under the ACUVUE brand. Company's two remaining segments primarily serve hospitals, healthcare professionals, wholesalers, and retailers, continuing its mission of advancing human health since its founding in 1886 and its current basing in New Brunswick, New Jersey.
Full JNJ Calculator →Save your analysis + weekly dividend insights. Free forever.
⚠️ Educational purposes only. Not financial advice. Congressional trades sourced from SEC STOCK Act filings via FMP. Past performance does not guarantee future results.